What You Didn’t Know About the Successful Seattle Genetics CEO– Clay Siegall
Clay Siegall is the founder and the current Chief Executive Officer of Seattle Genetics, a biotech firm based in Seattle. The renowned doctor and his team specialize in the advancement of therapy drugs that would help reduce mortality rates caused by different diseases like cancer. The competent doctor has greatly transformed the medical field through series of innovation and collaboration with medical companies.
How He Made Seattle Genetics a Success
Clay Siegall is a dedicated and competent CEO, and because of his innovative ideas, he managed to steer the growth of his company. Since 1998, the successful doctor has ensured that his team works in different researches to improve the medical field. The company introduced the first antibody-drug conjugate that was approved by FDA and has since then developed over 20 drugs in the therapy industry. Because of the innovations, Seattle Genetics continues to work with big drug manufacturers including Pfizer, Bayer, and Genentech. With the company’s drug portfolio, Dr. Clay Siegall still believes that his team still has much to do to ensure that cancer is no longer a killer disease across the world.
His Perception of Success in Business
Clay Siegall believes that success is when the consumers are satisfied, and the business can get even more demands. To him, one can only achieve success through hard work. The Doctor explained that many people always fail to recognized evolution; if business owners acknowledge the changing market trend and passionately work towards adapting to these, they would achieve success. He concludes that having success is a level field since factors like IQ, education background, and connections are just secondary influencers of success.
About Clay Siegall
Clay Siegall is not only the CEO of Seattle Genetics but also the Board of Directors Chairman and the company President. Before Dr. Clay Siegall founded Seattle Genetics, he was working with the Research Institute of Pharmaceutical Rea Bristol-Myers Squibb between 1991 and 1997. He then joined the National Institutes of Health and National Cancer Institute 1988 where he worked till 1991. He is currently serving as the member of Alder BioPharmaceuticals Board of Directors.